| Name | Title | Contact Details |
|---|
Perimed is a North Royalton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Veritas Health Solutions is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avantis Medical Systems Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sunnyvale, CA. To find more information about Avantis Medical Systems Inc., please visit www.avantismedical.com
NextHealth Technologies (NHT), based in Denver CO, drives measurable medical cost reduction through a prescriptive analytics and consumer engagement platform. NextHealth’s proprietary SaaS platform integrates three foundational technologies - prescriptive analytics, behavioral economics, and multichannel consumer engagement. This end-to end, technology-enabled solution predicts risk reduction opportunities and then prescribes personalized member level actions or “nudges" to dramatically improve outcomes. NHT has been able to deliver a sustained and ground breaking 25% reduction in ER visits and over $17 per member per year in medical claims cost reduction for targeted commercial, ASO, and Medicaid populations. NHT offers over 30+ use cases including ER visit reduction, out-of-network reduction, and retention of high value individual members. NextHealth offers an at risk managed services contract based on 20% of causal claims savings. These results have led the company to be named by Gartner as one of the most innovative healthcare analytics vendors in the US. NHT’s multi-year software and managed services solution is currently contracted and supporting over 1.5 million members with some of the most reputable health plans in the country including: UnitedHealthcare, BlueCross BlueShield of Tennessee, and Colorado Access.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.